134 related articles for article (PubMed ID: 32243670)
1. A combination of total tau and neurofilaments discriminates between neurodegenerative and primary psychiatric disorders.
Fourier A; Formaglio M; Kaczorowski F; Mollion H; Perret-Liaudet A; Sauvee M; Quadrio I
Eur J Neurol; 2020 Jul; 27(7):1164-1169. PubMed ID: 32243670
[TBL] [Abstract][Full Text] [Related]
2. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias.
Abu-Rumeileh S; Capellari S; Stanzani-Maserati M; Polischi B; Martinelli P; Caroppo P; Ladogana A; Parchi P
Alzheimers Res Ther; 2018 Jan; 10(1):3. PubMed ID: 29368621
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders.
Vijverberg EG; Dols A; Krudop WA; Del Campo Milan M; Kerssens CJ; Gossink F; Prins ND; Stek ML; Scheltens P; Teunissen CE; Pijnenburg YA
Alzheimers Dement (Amst); 2017; 7():99-106. PubMed ID: 28337476
[TBL] [Abstract][Full Text] [Related]
4. Association of Cerebrospinal Fluid Neurofilament Light Protein Levels With Cognition in Patients With Dementia, Motor Neuron Disease, and Movement Disorders.
Olsson B; Portelius E; Cullen NC; Sandelius Å; Zetterberg H; Andreasson U; Höglund K; Irwin DJ; Grossman M; Weintraub D; Chen-Plotkin A; Wolk D; McCluskey L; Elman L; Shaw LM; Toledo JB; McBride J; Hernandez-Con P; Lee VM; Trojanowski JQ; Blennow K
JAMA Neurol; 2019 Mar; 76(3):318-325. PubMed ID: 30508027
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.
Eratne D; Loi SM; Li QX; Stehmann C; Malpas CB; Santillo A; Janelidze S; Cadwallader C; Walia N; Ney B; Lewis V; Senesi M; Fowler C; McGlade A; Varghese S; Ravanfar P; Kelso W; Farrand S; Keem M; Kang M; Goh AMY; Dhiman K; Gupta V; Watson R; Yassi N; Kaylor-Hughes C; Kanaan R; Perucca P; Dobson H; Vivash L; Ali R; O'Brien TJ; Hansson O; Zetterberg H; Blennow K; Walterfang M; Masters CL; Berkovic SF; Collins S; Velakoulis D;
Alzheimers Dement; 2022 Nov; 18(11):2218-2233. PubMed ID: 35102694
[TBL] [Abstract][Full Text] [Related]
6. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study.
Abu-Rumeileh S; Mometto N; Bartoletti-Stella A; Polischi B; Oppi F; Poda R; Stanzani-Maserati M; Cortelli P; Liguori R; Capellari S; Parchi P
J Alzheimers Dis; 2018; 66(2):551-563. PubMed ID: 30320576
[TBL] [Abstract][Full Text] [Related]
8. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
9. Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis.
Lardeux P; Fourier A; Peter E; Dorey A; Muñiz-Castrillo S; Vogrig A; Picard G; Rogemond V; Verdurand M; Formaglio M; Joubert B; Froment Tilikete C; Honnorat J; Quadrio I; Desestret V
J Neurol; 2022 Jan; 269(1):377-388. PubMed ID: 34104991
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid neurofilament light chain differentiates behavioural variant frontotemporal dementia progressors from non-progressors.
Eratne D; Keem M; Lewis C; Kang M; Walterfang M; Farrand S; Loi S; Kelso W; Cadwallader C; Berkovic SF; Li QX; Masters CL; Collins S; Santillo A; Velakoulis D;
J Neurol Sci; 2022 Nov; 442():120439. PubMed ID: 36201960
[TBL] [Abstract][Full Text] [Related]
11. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid neurofilament light predicts longitudinal diagnostic change in patients with psychiatric and neurodegenerative disorders.
Kang MJY; Eratne D; Dobson H; Malpas CB; Keem M; Lewis C; Grewal J; Tsoukra V; Dang C; Mocellin R; Kalincik T; Santillo AF; Zetterberg H; Blennow K; Stehmann C; Varghese S; Li QX; Masters CL; Collins S; Berkovic SF; Evans A; Kelso W; Farrand S; Loi SM; Walterfang M; Velakoulis D
Acta Neuropsychiatr; 2024 Feb; 36(1):17-28. PubMed ID: 37114460
[TBL] [Abstract][Full Text] [Related]
13. Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease.
Gangishetti U; Christina Howell J; Perrin RJ; Louneva N; Watts KD; Kollhoff A; Grossman M; Wolk DA; Shaw LM; Morris JC; Trojanowski JQ; Fagan AM; Arnold SE; Hu WT
Alzheimers Res Ther; 2018 Sep; 10(1):98. PubMed ID: 30253800
[TBL] [Abstract][Full Text] [Related]
14. Clinical indications for analysis of Alzheimer's disease CSF biomarkers.
Engelborghs S
Rev Neurol (Paris); 2013 Oct; 169(10):709-14. PubMed ID: 24016466
[TBL] [Abstract][Full Text] [Related]
15. Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation.
Fialova L; Bartos A; Svarcova J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Sep; 161(3):286-295. PubMed ID: 28947837
[TBL] [Abstract][Full Text] [Related]
16. Plasma and CSF biomarkers for the diagnosis of Alzheimer's disease in adults with Down syndrome: a cross-sectional study.
Fortea J; Carmona-Iragui M; Benejam B; Fernández S; Videla L; Barroeta I; Alcolea D; Pegueroles J; Muñoz L; Belbin O; de Leon MJ; Maceski AM; Hirtz C; Clarimón J; Videla S; Delaby C; Lehmann S; Blesa R; Lleó A
Lancet Neurol; 2018 Oct; 17(10):860-869. PubMed ID: 30172624
[TBL] [Abstract][Full Text] [Related]
17. Revisiting the Cerebrospinal Fluid Biomarker Profile in Idiopathic Normal Pressure Hydrocephalus: The Bologna Pro-Hydro Study.
Abu-Rumeileh S; Giannini G; Polischi B; Albini-Riccioli L; Milletti D; Oppi F; Stanzani-Maserati M; Capellari S; Mantovani P; Palandri G; Cortelli P; Cevoli S; Parchi P
J Alzheimers Dis; 2019; 68(2):723-733. PubMed ID: 30883350
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.
Mattsson N; Insel PS; Palmqvist S; Portelius E; Zetterberg H; Weiner M; Blennow K; Hansson O;
EMBO Mol Med; 2016 Oct; 8(10):1184-1196. PubMed ID: 27534871
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease.
Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Floris R; Garaci F; Hampel H;
Neurochem Int; 2017 Sep; 108():355-360. PubMed ID: 28527630
[TBL] [Abstract][Full Text] [Related]
20. Cerebrospinal Fluid and Plasma Biomarkers do not Differ in the Presenile and Late-Onset Behavioral Variants of Frontotemporal Dementia.
Marelli C; Hourregue C; Gutierrez LA; Paquet C; Menjot de Champfleur N; De Verbizier D; Jacob M; Dubois J; Maleska AM; Hirtz C; Navucet S; Bennys K; Dumurgier J; Cognat E; Berr C; Magnin E; Lehmann S; Gabelle A
J Alzheimers Dis; 2020; 74(3):903-911. PubMed ID: 32083577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
